Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Terconazole. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 19/20 | 0.89 |
| ▸ | LMNA | P02545 | 3/20 | 0.89 |
| ▸ | CYP51A1 | Q16850 | 3/20 | 0.89 |
| ▸ | FYN | P06241 | 2/20 | 0.89 |
| ▸ | NR1I2 | O75469 | 2/20 | 0.89 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.89 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.89 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.89 |
| ▸ | TSHR | P16473 | 2/20 | 0.89 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.89 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.89 |
| ▸ | HTR2A | P28223 | 2/20 | 0.89 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.89 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.89 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.89 |
| ▸ | PGR | P06401 | 1/20 | 0.89 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.89 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.89 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.89 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.89 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Terconazole SCHEMBL7601910 | 0.94 | CYP3A4 (1.00) | CYP3A4LMNACYP51A1FYNNR1I2 | |
| Terconazole SCHEMBL29388408 | 0.94 | CYP3A4 (1.00) | CYP3A4LMNACYP51A1FYNNR1I2 | |
| Terconazole SCHEMBL18258318 | 0.94 | CYP3A4 (1.00) | CYP3A4LMNACYP51A1FYNNR1I2 | |
| Terconazole SCHEMBL17493426 | 0.94 | CYP3A4 (1.00) | CYP3A4LMNACYP51A1FYNNR1I2 | |
| Terconazole SCHEMBL4924542 | 0.94 | CYP3A4 (1.00) | CYP3A4LMNACYP51A1FYNNR1I2 | |
| Terconazole SCHEMBL5008913 | 0.94 | CYP3A4 (1.00) | CYP3A4LMNACYP51A1FYNNR1I2 | |
| Terconazole SCHEMBL23165 | 0.94 | CYP3A4 (1.00) | CYP3A4LMNACYP51A1FYNNR1I2 | |
| Terconazole SCHEMBL9043676 | 0.94 | CYP3A4 (0.98) | CYP3A4LMNACYP51A1FYNNR1I2 | |
| Terconazole SCHEMBL4923831 | 0.94 | CYP3A4 (0.98) | CYP3A4LMNACYP51A1FYNNR1I2 | |
| Terconazole SCHEMBL6233263 | 0.92 | CYP3A4 (0.89) | CYP3A4LMNACYP51A1FYNNR1I2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1494630-A4 | BIOADHESIVE DRUG DELIVERY SYSTEM | DRUGTECH CORP (US) | 2007-03-14 | — | — | EP | claimed |
| US-6899890-B2 | Bioadhesive drug delivery system | KV PHARMACEUTICAL COMPANY (US) | 2005-05-31 | — | — | US | claimed |
| EP-1494630-A2 | BIOADHESIVE DRUG DELIVERY SYSTEM | Drugtech Corporation (US) | 2005-01-12 | — | — | EP | claimed |
| WO-2003079981-A2 | BIOADHESIVE DRUG DELIVERY SYSTEM | DRUGTECH CORPORATION (US) | 2003-10-02 | — | — | WO | claimed |
| US-20030180366-A1 | Bioadhesive drug delivery system | PADAGIS US LLC | 2003-09-25 | — | — | US | claimed |
| CN-106456781-B | Hydroalcoholic system for nail treatment | 圣地亚哥-德孔波斯特拉大学 | 2020-07-10 | — | — | CN | disclosed |
| US-20150087000-A1 | DIAGNOSTIC KITS TO DETECT SP22 AND SP22 ANTIBODIES | U.S. ENVIRONMENTAL PROTECTION AGENCY | 2015-03-26 | — | — | US | disclosed |
| US-8497135-B2 | Diagnostic kits to detect SP22 and SP22 antibodies | U.S. ENVIRONMENTAL PROTECTION AGENCY (US) | 2013-07-30 | — | — | US | disclosed |
| US-8057433-B2 | Delivery system | DRUGTECH CORPORATION (US) | 2011-11-15 | — | — | US | disclosed |
| US-20110276030-A9 | DELIVERY SYSTEM | DRUGTECH CORPORATION (US) | 2011-11-10 | — | — | US | disclosed |
| US-8012932-B2 | Contacting male ejaculate, prior to contact with a female egg, with an effective anti-fertility amount of a pharmaceutical composition, which comprises an antibody that binds a surface exposed epitope of SP22, and a pharmaceutically acceptable carrier | U.S. ENVIRONMENTAL PROTECTION AGENCY (US) | 2011-09-06 | — | — | US | disclosed |
| US-20110020350-A1 | Contraceptives Based on SP22 and SP22 Antibodies | KLINEFELTER GARY R | 2011-01-27 | — | — | US | disclosed |
| WO-2006012539-A1 | CONTRACEPTIVES BASED ON SP22 AND SP22 ANTIBODIES | U.S. ENVIRONMENTAL PROTECTION AGENCY (US) | 2006-02-02 | — | — | WO | disclosed |
| US-6899890-B2 | Bioadhesive drug delivery system | KV PHARMACEUTICAL COMPANY (US) | 2005-05-31 | — | — | US | disclosed |
| EP-1519704-A2 | SPHERICAL PELLET CONTAINING A WATER-SOLUBLE ACTIVE INGREDIENT | Cilag AG (CH) | 2005-04-06 | — | — | EP | disclosed |
| US-20050069536-A1 | Contraceptives based on SP22 and SP22 antibodies | U.S. ENVIRONMENTAL PROTECTION AGENCY (US) | 2005-03-31 | — | — | US | disclosed |
| EP-1494630-A2 | BIOADHESIVE DRUG DELIVERY SYSTEM | Drugtech Corporation (US) | 2005-01-12 | — | — | EP | disclosed |
| WO-2004002398-A2 | SPHERICAL PELLET CONTAINING A WATER-SOLUBLE ACTIVE INGREDIENT | CILAG AG (CH) | 2004-01-08 | — | — | WO | disclosed |
| WO-2003079981-A2 | BIOADHESIVE DRUG DELIVERY SYSTEM | DRUGTECH CORPORATION (US) | 2003-10-02 | — | — | WO | disclosed |
| US-20030180366-A1 | Bioadhesive drug delivery system | PADAGIS US LLC | 2003-09-25 | — | — | US | disclosed |